drugset / Trial / NCT00914849

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

NCT00914849 ↗

Phase 2 Completed 68 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.

Timeline

Start
2009-08
Primary completion
2011-01
Completion
2012-02

Outcome

Missed primary endpoint

paper The primary outcome of reducing the failure to collect ≥2 × 106 CD34+/kg recipient weight in 1 apheresis collection to ≤10% was not reached. PMID 28292947 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AMD3100 Small molecule 320 ug/kg Intravenous